 Theratechnologies Inc NASDAQ: THTX has completed discussions with the FDA and European Medicines Agency regarding its proposed trial design and protocol for its Phase 3 trial for tesamorelin in nonalcoholic steatohepatitis NASH. The trial will include a futility analysis after approximately 400 patients have completed 18 months of treatment and have received a second liver biopsy. 